Antisense oligonucleotide - AstraZeneca/Ionis Pharmaceuticals
Latest Information Update: 28 May 2024
At a glance
- Originator Ionis Pharmaceuticals
- Developer AstraZeneca; Ionis Pharmaceuticals
- Class Antineoplastics; Antisense oligonucleotides
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2024 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)